SCHEMBL6482910

SCHEMBL6482910

CCN(CC)c1ccc(CCCc2ccc(Nc3cccc(C(=O)O)c3)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
MAPT P10636 3/20 0.54
NOX1 Q9Y5S8 2/20 0.54
ALDH1A1 P00352 2/20 0.54
MAPK1 P28482 2/20 0.54
USP2 O75604 1/20 0.54
TP53 P04637 1/20 0.54
PKM P14618 1/20 0.54
TSHR P16473 1/20 0.54
MCL1 Q07820 1/20 0.54
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
AKR1C3 P42330 3/20 0.48
AKR1C2 P52895 3/20 0.48
ADRB1 P08588 1/20 0.47
ADRB3 P13945 1/20 0.47
RHOA P61586 1/20 0.45
LMNA P02545 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6484606 0.87 RARB (0.50) MEN1KMT2AMAPTNOX1ALDH1A1
SCHEMBL6475709 0.79 MAPT (0.43) MEN1KMT2AMAPTNOX1ALDH1A1
SCHEMBL6474928 0.77 SIRT1 (0.50) MEN1KMT2ANOX1NPC1RAB9A
SCHEMBL6474913 0.77 MEN1 (0.55) MEN1KMT2AMAPTNOX1ALDH1A1
SCHEMBL6484538 0.74 MEN1 (0.58) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL6475251 0.73 MEN1 (0.56) MEN1KMT2AMAPTALDH1A1AKR1C3
SCHEMBL6484033 0.73 KMT2A (0.43) MEN1KMT2AMAPTNOX1ALDH1A1
SCHEMBL6474710 0.73 MEN1 (0.62) MEN1KMT2AMAPTALDH1A1MAPK1
3-Phenylamino Benzoic Acid SCHEMBL4345076 0.72 RHOA (0.77) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL9514595 0.72 NPC1 (0.68) MEN1KMT2AMAPTNOX1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US claimed
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 MEN1 474/4885KMT2A 4729/4885MAPT 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.